HDAC9 and cancer: The results of this study show that fisetin alone or in combination with an HDAC inhibitors reagent attenuated liver cancer cell viability in a dose-dependent manner, and thus that fisetin could be a beneficial cancer therapy and a potential treatment for multidrug-resistant cancers.